Core Viewpoint - Heng Rui Medicine's subsidiary, Shanghai Heng Rui Medicine Co., Ltd., has announced that its injectable SHR-1501 has been included in the list of proposed breakthrough therapeutic varieties by the National Medical Products Administration's Drug Review Center, with a public announcement period of 7 days [1] Group 1 - SHR-1501 is a proprietary interleukin-15 (IL-15) fusion protein developed by the company [1] - The drug stimulates the proliferation of T cells, B cells, and NK cells in the body, enhancing the immune system's ability to eliminate foreign substances such as tumors [1] - When used in conjunction with BCG, SHR-1501 significantly enhances the immune response within the bladder, achieving a synergistic anti-tumor effect [1]